Pluristem Therapeutics, Inc.(NASDAQ : PSTI)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||2.71%||461.57||2.7%||$556.12m|
|GILD||Gilead Sciences, Inc.||2.20%||64.62||1.0%||$516.91m|
|VRTX||Vertex Pharmaceuticals, Inc.||2.02%||211.98||1.9%||$458.30m|
|ALXN||Alexion Pharmaceuticals, Inc.||1.11%||150.10||2.0%||$339.49m|
|CRSP||CRISPR Therapeutics AG||-0.73%||114.65||0.6%||$304.78m|
|BNGO||BioNano Genomics, Inc.||3.62%||7.15||0.0%||$275.81m|
|EXAS||EXACT Sciences Corp.||0.51%||121.64||18.4%||$251.13m|
|PACB||Pacific Biosciences of California, Inc.||1.70%||29.27||7.2%||$176.23m|
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.